An observational study in Low Anterior Resection Syndrome, Faecal Incontinence With Faecal Urgency and Faecal Incontinence, sponsored by Aalborg University Hospital. Recruiting at 3 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.
Sponsored by Aalborg University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational study is to learn why some patients develop low anterior resection syndrome (LARS) after colorectal cancer treatment. The study also aims to identify different subtypes of LARS and understand which patients may respond to specific treatments.
The main questions it aims to answer are:
Participants will:
Be compared with four control groups:
Low anterior resection syndrome (LARS) is a common long-term complication after colorectal cancer surgery. Up to 80% of patients experience symptoms such as urgency, frequent bowel movements, clustering, and fecal incontinence. These symptoms can severely affect quality of life, and the underlying causes are not fully understood. LARS appears to result from several interacting mechanisms, including sensory changes, altered motility, reduced reservoir function, sphincter dysfunction, and effects of chemotherapy or radiotherapy. Because different patients may have different dominant mechanisms, treatment responses vary widely.
This observational study aims to investigate the physiological and imaging characteristics of LARS using advanced assessment methods. The goal is to better understand the mechanisms behind LARS, identify distinct patient subtypes, and support development of more targeted treatment strategies.
The study will include 50 patients with minor or major LARS after rectal cancer surgery. Their results will be compared with four control groups:
All participants will attend a single study visit that includes advanced physiological measurements, Magnetic Resonance Imaging (MRI)-based assessments, and standardized questionnaires. These methods are not part of routine clinical care but are used to explore mechanisms such as motility, sensory function, sphincter activity, and rectal reservoir function.
Patients with LARS will also be followed during their standard stepwise treatment pathway. They will complete questionnaires before and during each treatment step, which may include dietary advice, medication, pelvic floor training (biofeedback), and rectal emptying techniques such as mini-enemas or transanal irrigation. This follow-up will help determine how different physiological patterns relate to treatment response.
The study is conducted in collaboration between Aarhus University Hospital and Aalborg University Hospital, with expert input from The Royal London Hospital (UK) and Motilis SA (Switzerland).
82 studies on the registry are indexed under Low Anterior Resection Syndrome; 38 are open to participants now.
This study's planned enrollment of 145 is above the median of 125 across 25 observational studies indexed under Low Anterior Resection Syndrome.
Browse Low Anterior Resection Syndrome studies →Aalborg University Hospital is the lead sponsor of 198 studies on the registry; 41 are open to participants now.
Counted across the registry records on this site, refreshed daily.
During outpatient visits, the treatment responsible doctor will identify eligible patients. Patients will be recruited at the following departments:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
General:
Specific inclusion criteria for LARS patients:
Specific inclusion criteria for fecal incontinence patients and urge fecal incontinence patients
Specific inclusion criteria for "watch and wait" patients:
Exclusion Criteria:
General exclusion criteria
Specific exclusion criterias for LARS patients
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LARS score ≥ 20; Patients operated for rectal cancer with a rectal resection and sphincter preserving surgery at a minimum of three months postoperative. If patients have received a temporary protective ileostomy, this should have been reversed for a minimum of three months postoperative.
LARS score \< 20; Patients operated for rectal cancer with a rectal resection and sphincter preserving surgery at a minimum of three months postoperative. If patients have received a temporary protective ileostomy, this should have been reversed for a minimum of three months postoperative.
* Patients planned for neuromodulation * Satisfactory interoperative test results leading to permanent implantation of a pacemaker for sacral nerve modulation
* Patients planned for neuromodulation * Satisfactory interoperative test results leading to permanent implantation of a pacemaker for sacral nerve modulation * Faecal urgency occurring ≥3 episodes per week, with or without associated Faecal incontinence (≥1 episode per week), and a St. Mark's Incontinence Score of ≥9
Rectum/colon cancer patients treated with organ-preserving treatment, i.e., chemotherapy and radiotherapy with a complete clinical and radiological response at a minimum of 12 months posttreatment
EuroQol 5-Dimension, 5-Level quality-of-life questionnaire
The EuroQol 5-Dimension, 5-Level questionnaire assesses generic health-related quality of life across five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain has five response levels ranging from "no problems" to "extreme problems." Score range and direction: Higher scores indicate better health-related quality of life. Includes a visual analogue scale (0-100) where higher scores indicate better self-rated health.
Time frame: From baseline visit to the end of each standardized treatments at 4 weeks
Low Anterior Resection Syndrome Score
The Low Anterior Resection Syndrome (LARS) Score is a disease-specific symptom questionnaire assessing bowel dysfunction after low anterior resection. It includes five items covering incontinence, frequency, clustering, urgency, and impact on daily life. Score range and direction: Total score ranges from 0 to 42. Higher scores indicate more severe bowel dysfunction. Severity categories: 0-20: No LARS 21-29: Minor LARS 30-42: Major LARS
Time frame: From baseline visit to the end of each standardized treatments at 4 weeks
St Mark's Incontinence score
Description: The St. Mark's Incontinence Score assesses the severity of fecal incontinence across multiple domains, including incontinence to gas, liquid, and solid stool, urgency, use of pads, and lifestyle impact. Score range and direction: Total score ranges from 0 to 24. Higher scores indicate more severe fecal incontinence.
Time frame: • Applied at baseline and four weeks into all treatment periods
Colostomy Impact Score
The Colostomy Impact Score is a disease-specific questionnaire evaluating the impact of living with a colostomy on daily functioning, social participation, body image, and emotional well-being. Score range and direction: Total score ranges from 0 to 100. Higher scores indicate greater negative impact of the colostomy on quality of life.
Time frame: From baseline visit to the end of each standardized treatments at 4 weeks
Bristol Stool Form Scale
The Bristol Stool Form Scale classifies stool consistency into seven categories ranging from hard, lumpy stools to entirely liquid stools. It is used as an indicator of bowel transit and stool form. Score range and direction: Scale ranges from Type 1 to Type 7. Lower types (1-2) indicate harder stools and slower transit. Middle types (3-4) indicate normal stool form. Higher types (6-7) indicate loose or watery stools and faster transit.
Time frame: From baseline visit to the end of each standardized treatments at 4 weeks
Patient Assessment of Constipation Symptoms (PAC-SYM)
The Patient Assessment of Constipation Symptoms questionnaire measures symptom severity in constipation across three domains: abdominal symptoms, stool symptoms, and rectal symptoms. Score range and direction: Each item is scored 0-4; total score ranges from 0 to 48. Higher scores indicate more severe constipation symptoms.
Time frame: From baseline visit to the end of each standardized treatments at 4 weeks
Wexner Incontinence Score
The Wexner Incontinence Score evaluates the severity of fecal incontinence based on frequency of incontinence to gas, liquid, and solid stool, need for pads, and lifestyle alteration. Score range and direction: Total score ranges from 0 to 20. Higher scores indicate more severe fecal incontinence.
Time frame: From baseline visit to the end of each standardized treatments at 4 weeks
Hospital Anxiety and Depression Scale (HADS)
The Hospital Anxiety and Depression Scale assesses symptoms of anxiety and depression in medical populations. It consists of two subscales: HADS-Anxiety and HADS-Depression. Score range and direction: Each subscale ranges from 0 to 21. Higher scores indicate more severe symptoms of anxiety or depression. Total score (0-42) may be reported but is less commonly used.
Time frame: From baseline visit to the end of each standardized treatments at 4 weeks
Whole gut and segmental transit times as measured with 3D-Transit
Whole-gut and segmental gastrointestinal transit times are measured using the Motilis 3D-Transit system. The system tracks the movement of an electromagnetic capsule through the gastrointestinal tract, allowing calculation of segmental transit times (stomach, small intestine, colon) and total whole-gut transit time. This measure evaluates gastrointestinal motility patterns at baseline. Score range and direction: Transit times are continuous measures reported in minutes or hours. There is no fixed upper or lower limit, as transit times vary physiologically between individuals. Longer transit times indicate slower gastrointestinal motility. Shorter transit times indicate faster gastrointestinal motility.
Time frame: At baseline
Colonic and segmental colonic volumes
Magnetic resonance imaging is used at baseline to quantify total colonic volume and segmental colonic volumes (ascending, transverse, descending, sigmoid/rectum colon). Volumes are derived from semi-automated segmentation of the colon on T2-weighted images. This measure evaluates baseline colonic morphology and storage capacity. Score range and direction: Colonic volumes are continuous measures reported in milliliters (mL). There is no fixed upper or lower limit, as volumes vary physiologically between individuals. Higher values indicate larger colonic or segmental volume. Lower values indicate smaller colonic or segmental volume.
Time frame: At baseline
Resting Anal Pressure Measured by High-Resolution Anorectal Manometry
Resting anal pressure will be measured using high-resolution anorectal manometry according to standard manometric protocols. Resting anal pressure reflects basal anal sphincter tone, primarily related to internal anal sphincter function. The outcome will be reported as a continuous physiological measure in millimeters of mercury (mmHg). There are no fixed minimum or maximum values because pressures vary physiologically between individuals. Higher values indicate higher resting anal sphincter tone, while lower values indicate reduced resting sphincter tone.
Time frame: At baseline
Maximal Voluntary Anal Squeeze Pressure Measured by High-Resolution Anorectal Manometry
Maximal voluntary anal squeeze pressure will be measured using high-resolution anorectal manometry according to standard manometric protocols. Squeeze pressure reflects voluntary external anal sphincter contractile strength. The outcome will be reported as a continuous physiological measure in millimeters of mercury (mmHg). There are no fixed minimum or maximum values because pressures vary physiologically between individuals. Higher values indicate stronger voluntary anal sphincter contraction, while lower values indicate reduced voluntary sphincter contractile function.
Time frame: At baseline
Rear-Front Pressure Gradient Measured by the Fecobionics Device
The rear-front pressure gradient will be measured using the Fecobionics device during simulated stool evacuation. The Fecobionics device records axial pressure patterns during defecation. The rear-front pressure gradient reflects the pressure difference between the rear and front sensors of the device during evacuation and provides a measure of propulsive force relative to outlet resistance. The outcome will be reported as a continuous physiological measure in millimeters of mercury (mmHg). There are no fixed minimum or maximum values because values vary physiologically between individuals. Higher values indicate stronger propulsive pressure relative to outlet resistance, whereas lower values may indicate impaired propulsion or increased outlet resistance.
Time frame: At baseline
Compare the physiological findings in LARS patients with controls
Compare the physioligal findings in LARS patients with a) no-LARS patients, b) organ-preservation patients and c) patient with fecal incontinence
Time frame: At baseline
Investigate the physiological changes in anorectal function associated with neuromodulation in patients with urge fecal incontinence
Changes in anorectal function measured by the Fecobionics Device
Time frame: From baseline to after 30 minutes of active neuromodulation
Investigate the physiological changes in anorectal function associated with neuromodulation in patients with urge fecal incontinence
Changes in anorectal function measured by high-resolution anorectal manometry
Time frame: From baseline to after 30 minutes of active neuromodulation
Investigate the physiological changes in anorectal function associated with neuromodulation in patients with fecal incontinence
Changes in anorectal function measured by the Fecobionics Device
Time frame: From baseline to after active neuromodulation at Visit 2
Investigate the physiological changes in anorectal function associated with neuromodulation in patients with fecal incontinence
Changes in anorectal function measured by high-resolution anorectal manometry
Time frame: From baseline to after active neuromodulation at Visit 2
Change in VAS Urgency Score From Before to During Stimulation at the Baseline Visit
The participant's perceived urgency to defecate during the examination will be assessed using a visual analogue scale. Participants with fecal incontinence will rate their urgency to defecate on a numeric scale from 0 to 10, where 0 indicates no desire to defecate and 10 indicates maximal urgency. The outcome will be reported as the change in VAS urgency score from the pre-stimulation assessment to the stimulation assessment at the baseline visit. Higher scores indicate stronger urgency to defecate.
Time frame: Baseline visit: immediately before stimulation and during active stimulation
Resting-State Electroencephalography
Resting-state electroencephalography is recorded with the participant at rest to assess baseline cortical activity patterns. Measures include spectral power across standard frequency bands (theta, alpha, beta). Score range and direction: Spectral power values are continuous and do not have fixed upper limits. Higher or lower values reflect differences in cortical activity depending on frequency band.
Time frame: At baseline
Evoked Potential Amplitude During Rectal Balloon Distension
Electroencephalography is recorded during rapid rectal balloon distension to elicit cortical evoked potentials. The primary measure is the amplitude of the evoked response to visceral stimulation. Score range and direction: Amplitude is measured in microvolts (µV). Higher amplitudes indicate stronger cortical responses to visceral stimulation.
Time frame: At baseline
Evoked Potential Latency During Rectal Balloon Distension
Electroencephalography is recorded during rectal balloon distension to measure the latency of cortical evoked potentials, reflecting the timing of sensory pathway activation. Score range and direction: Latency is measured in milliseconds (ms). Longer latencies indicate slower or delayed cortical processing. Shorter latencies indicate faster neural conduction.
Time frame: At baseline
Defecation Index Measured by the Fecobionics Device
The defecation index will be derived from Fecobionics measurements obtained during simulated stool evacuation. The index summarizes expulsion performance and anorectal function based on prespecified Fecobionics-derived variables. The outcome will be reported as a continuous index value. There are no fixed minimum or maximum values. Higher values indicate more efficient expulsion and better defecatory performance, whereas lower values indicate reduced defecatory performance.
Time frame: Baseline
Not enrolling at this site.
Plan to share: No — Individual participant data will not be shared because the study involves sensitive health information and data protection regulations (GDPR) prevent public sharing of identifiable or de-identified participant-level data.
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.
Of 18 observational studies under Low Anterior Resection Syndrome, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 34. This study's planned 27 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Low Anterior Resection Syndrome →